{"id":"montelukast-oral-granules-og","safety":{"commonSideEffects":[{"rate":"18","effect":"Headache"},{"rate":"7","effect":"Pharyngitis"},{"rate":"6","effect":"Diarrhea"},{"rate":"5","effect":"Nausea"},{"rate":"4","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1200681","moleculeType":"Small molecule","molecularWeight":"608.18"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Montelukast is a selective antagonist of the cysteinyl leukotriene type-1 (CysLT1) receptor. Leukotrienes are inflammatory mediators released by mast cells and eosinophils that cause airway constriction, mucus secretion, and eosinophil recruitment. By blocking these receptors, montelukast reduces airway inflammation and improves airflow in asthma and allergic rhinitis.","oneSentence":"Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and inflammatory cells, preventing leukotriene-mediated bronchoconstriction and inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:07.576Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma (prophylaxis and chronic treatment)"},{"name":"Allergic rhinitis"},{"name":"Exercise-induced bronchoconstriction"}]},"trialDetails":[{"nctId":"NCT01852812","phase":"PHASE3","title":"Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-06-07","conditions":"Perennial Allergic Rhinitis","enrollment":87},{"nctId":"NCT00540839","phase":"PHASE3","title":"A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2007-11","conditions":"Asthma, Bronchial","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Montelukast Oral Granules (OG)","genericName":"Montelukast Oral Granules (OG)","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and inflammatory cells, preventing leukotriene-mediated bronchoconstriction and inflammation. Used for Asthma (prophylaxis and chronic treatment), Allergic rhinitis, Exercise-induced bronchoconstriction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}